Switching from one generic alendronate to another - a common procedure in Poland in the years 2001-2005

Edward Franek; Marek Tałałaj; Hanna Wichrowska; Beata Czerwieńska; Rafał Filip; Krzysztof Safranow; Ewa Marcinowska-Suchowierska; Andrzej Więcek

Vol 62, No 1 (2011)

Original paper

Submitted: 2013-02-15

Published online: 2011-03-01

View PDF

Download PDF file

Get Citation

Switching from one generic alendronate to another - a common procedure in Poland in the years 2001-2005

Edward Franek, Marek Tałałaj, Hanna Wichrowska, Beata Czerwieńska, Rafał Filip, Krzysztof Safranow, Ewa Marcinowska-Suchowierska, Andrzej Więcek

Endokrynol Pol 2011;62(1):14-17.

Vol 62, No 1 (2011)

Original Paper

Submitted: 2013-02-15

Published online: 2011-03-01

Abstract

Introduction: In clinical ambulatory practice, patients often, rather than discontinuing treatment, change to another one. This study aims to assess the reasons why patients with osteoporosis switch from one alendronate to another with a different brand name.
Material and methods: A retrospective analysis of 747 bisphosphonate-treated patients was performed (651 female, average age 67.3 ± 8.9 years, BMI 26.5 ± 4.0 kg/m²). The frequency and reasons for drug switching during the 19.4 ± 13.4 months of observation were analysed.
Results: In 387 (51.8%) patients, treatment was not changed during the observation period, whereas in 360 (48.2%) patients, at least one drug switch occurred. Almost 40% of patients from that group (138 patients) switched from one alendronate to another alendronate with a different brand name. The most frequent reasons were: adverse event (36.9%), high price of the drug (23.2%) and request of patient (16.7%).
Conclusions: A substantial proportion of persistent bisphosphonate-treated patients switch treatment from one alendronate to another. The most frequent reasons for that kind of switching are the occurrence of an adverse event and the high cost of treatment. (Pol J Endocrinol 2011; 62 (1): 14-17)